Career history of Hans Louis Jos de Winter
Former positions of Hans Louis Jos de Winter
Companies | Position | Start | End |
---|---|---|---|
Silicos SA
Silicos SA Pharmaceuticals: MajorHealth Technology Silicos, founded in June 2005, is a chemo-informatics-based biotechnology company empowering proprietary multi-target virtual screening technologies for the discovery of novel and high-quality lead compounds for the treatment of a large variety of diseases, such as cancer, infectious diseases, central nervous system and immunodeficiency diseases. Silicos' proprietary virtual screening technology is based on a unique concept called Spectrophores™, which are descriptors representing all possible three-dimensional molecular properties involved in the binding of a drug to its receptor. Cosmos™ is Silicos' platform for the de novo design of new small molecules optimized towards one or multiple targets. | Director/Board Member | 09/05/2010 | 10/05/2012 |
Chief Tech/Sci/R&D Officer | 31/12/2004 | 10/05/2012 | |
Founder | 31/12/2004 | 10/05/2012 | |
Victoria University | Corporate Officer/Principal | - | - |
The Janssen Research Foundation | Chief Tech/Sci/R&D Officer | 31/12/1995 | - |
Training of Hans Louis Jos de Winter
Université Catholique de Louvain | Undergraduate Degree |
Statistics
International
Belgium | 3 |
United States | 2 |
Australia | 2 |
Operational
Chief Tech/Sci/R&D Officer | 2 |
Director/Board Member | 1 |
Founder | 1 |
Sectoral
Consumer Services | 3 |
Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 2 |
---|---|
Silicos SA
Silicos SA Pharmaceuticals: MajorHealth Technology Silicos, founded in June 2005, is a chemo-informatics-based biotechnology company empowering proprietary multi-target virtual screening technologies for the discovery of novel and high-quality lead compounds for the treatment of a large variety of diseases, such as cancer, infectious diseases, central nervous system and immunodeficiency diseases. Silicos' proprietary virtual screening technology is based on a unique concept called Spectrophores™, which are descriptors representing all possible three-dimensional molecular properties involved in the binding of a drug to its receptor. Cosmos™ is Silicos' platform for the de novo design of new small molecules optimized towards one or multiple targets. | Health Technology |
The Janssen Research Foundation |